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The causative organism of vertebral osteomyelitis (VO) was almost exclusively Staphylococcus aureus. The purpose of
this study was to delineate the differences in clinical features and outcomes between patients with methicillin-resistant
Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (MSSA) VO. This study retrospectively
reviewed 85 consecutive patients with VO treated between 2005 and 2011. Surgical site infections were excluded.
Diagnosis was made by cultures of either blood or biopsied samples. We identified 16 cases of MRSA VO and 14 cases
of MSSA VO. The average follow-up period was 18.5 months. Clinical features and outcomes were analyzed. Males were
more likely to have MRSA VO than MSSA VO (87.5% vs. 35.7%). In regards to the number of co-morbidities, patients
with MRSA VO had significantly more co-mobidities than patients with MSSA VO. Additionally, the rate of patients who
underwent surgical procedure (excluding spinal surgeries in the affected region) within 3 months were significantly
higher in the MRSA VO group than the MSSA VO group (56.3% vs. 14.3%). White blood cell counts and C-reactive
protein levels in patients with both strains significantly improved 4 weeks after the initial treatment compared with the
pretreatment values. The recurrence rate within 6 months tended to be higher for MRSA VO (37.5% vs. 7.1%), but no
significant difference in mortality was observed between the two VO types. In conclusion, male sex, multiple
co-morbidities and previous non-spine surgery were significant risk factors for VO due to MRSA as compared to MSSA.
The recurrence rate within 6 months tended to be higher for MRSA VO. Patients with MRSA VO should be monitored
carefully for recurrence by sequential clinical, radiographic, and laboratory examinations during the treatment course.
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VancomycinIntroduction
The number of patients with pyogenic vertebral osteomye-
litis (VO) has increased steadily in recent years (Zimmerli
2010; Mylona et al. 2009; Cebrián Parra et al. 2012). The
incidence of VO has been estimated to be 2.4 cases per
100,000 people and increases with increasing age (from
0.3 per 100,000 among people aged < 20 years to 6.5 per
100,000 among people aged >70 years) (Zimmerli 2010;
Cebrián Parra et al. 2012). In 1931, Hatch (1931) reviewed
the literature and reported that the causative organism* Correspondence: inoshin@hyo-med.ac.jp
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in any medium, provided the original work is pwas almost exclusively Staphylococcus aureus (SA). After
initiation of antibiotic use, Sapico and Montgomerie
(1980) reported in 1979 that 67% bacteria that caused
spinal infections were the gram-positive type, and 55%
were methicillin-sensitive Staphylococcus aureus (MSSA).
SA remains a common pathogen and a major cause of
morbidity and mortality (Zimmerli 2010; Mylona et al.
2009; Cebrián Parra et al. 2012; Yoon et al. 2010; Corrah
et al. 2011; Mete et al. 2012).
The first strains of methicillin-resistant Staphylococcus
aureus (MRSA) was reported in 1961 (Barber 1961).
Thereafter, the number of adult patients with MRSA
bacteremia increased with time and has been a growingOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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cant increase in mortality among patients who had
MRSA bacteremia compared with mortality among pa-
tients who had MSSA bacteremia (Cosgrove et al. 2003;
Shurland et al. 2007). In regards to other infectious dis-
eases (meningitis (Chang et al. 2001), endocarditis (Yoon
et al. 2005), arthritis (Al-Nammari et al. 2007a), liver
abscess (Ferreira et al. 2011), and spinal epidural abscess
(Huang et al. 2012)), there have been recent studies
comparing the clinical characteristics of infection caused
by MSSA and MRSA strains.
Recently, several authors have reported clinical charac-
teristics of MRSA spondylitis (Al-Nammari et al. 2007b;
Livorsi et al. 2008; Priest & Peacock 2005). However, few
studies have compared the clinical features of spondylitis
due to MSSA and MRSA. The purpose of the present
study was to delineate the differences in clinical features
and outcomes between patients with MRSA VO and
MSSA VO.
Materials and methods
This study design was approved by the review board of
our institute. We retrospectively reviewed 85 consecu-
tive patients who had pyogenic spondylitis treated be-
tween January 2005 and December 2011 at Hyogo
College of Medicine Hospital. Our facility is a 910-bed
tertiary care university hospital in Japan that provides
medical care to approximately 300,000 inpatients, in-
cluding over 8000 surgical operations, and services
600,000 outpatients per year. Our hospital has 34 highly
specialized medical treatment departments plus an
emergency department, and it has 26 medical treatment
centers/facilities, including a cancer center. On the basis
of the study by Al-Nammari et al. (2007b), we used the
following inclusion criteria in this study:
 No previous local spinal surgery at any time
 Compatible clinical history
 Compatible imaging
 MSSA or MRSA isolated from bone, intervertebral
disc, or paravertebral biopsies and/or MRSA or
MSSA isolated from blood cultures in patients with
a clinical and radiological history of spondylodiscitis
 Follow-up ≥ 6 months
 Case notes, image, and electronic patient record
available
A BacT-ALERT 3D (Sysmex-biomerieux, Tokyo, Japan)
was used for blood cultures. The Auto-Scan W/A and
Comb Panel (Siemens) and standard techniques were
used to identify isolates and determine susceptibility.
Microdilution using the methods of Clinical Laboratory
Standards Institute were used to determine methicillin
susceptibility.Thirty consecutive patients with SA VO met the inclu-
sion criteria (MSSA, 14 cases; MRSA 16, cases). The
patients’ demographic data, clinical characteristics, and
radiographic and laboratory features were recorded and
compared between the MSSA and MRSA strains. The
patient demographic data collected included age, gender,
height, weight, body mass index (BMI), and comorbi-
dities. Co-morbidities included heart disease, respiratory
disease, liver disease, urinary tract infection, hemodialysis,
diabetes mellitus, steroids use, malignancy, chemotherapy,
and postsurgical states. Use of the phrase “post-surgical
states” was meant for patient who underwent any invasive
surgeries within 3 months, excluding surgical site infection
after spinal surgery. Among clinical characteristics, pain
due to infection, fever (> 38°C), neurological deficit, and
septic shock and the onset of symptoms (classification of
(Kulowski 1936)) were reviewed. Radiographic features,
including the number, localization, and staging (classifica-
tion of (Griffiths & Jones 1971)) of the vertebral body
infections, were investigated using X-rays, and the pres-
ence of abscess was investigated by magnetic resonance
imaging (MRI). Laboratory features were evaluated by
obtaining white blood cell (WBC) counts, C-reactive pro-
tein (CRP) levels, and serum albumin (Alb) levels. Clinical
outcomes included antimicrobial duration, length of hos-
pital stay, surgical intervention, relapse and mortality
within 6 months, and laboratory findings (WBC counts
and CRP levels) at the 4th week after antibiotic treatment.
Surgical treatment is required if conservative treatments
are ineffective, if there is concomitant neurological deficit,
or if there is development or worsening of deformity due
to severe destruction of the anterior column. Relapse of
infection was defined as developed symptoms related to
recurrence of inflammation markers (WBC counts and
CRP levels) with or without worsening of radiographic
findings. Patient deaths were classified as either that
caused by infection or by the underlying disease.
Statistical analysis
All numerical results were presented as means ± SDs.
The unpaired t-test and Fisher’s exact probability test
were used to compare differences between the groups.
The paired t-test was used to compare continuous vari-
ables during the clinical course. P values < 0.05 were
considered to indicate statistical significance. Statistical
analysis was performed using SPSS Statistics 20.0 (IBM,
IL, USA).
Results
A positive microbiological diagnosis was made for 49
(57.6%) patients with VO (Table 1). The most frequently
identified organism was SA (30 patients, 61.2%). The
mean age and gender ratio (male/female) were 65.6 ±
13.4 years (range, 14–88 years) and 19/11, respectively.
Table 1 Causative organisms identified in the 49 cases of
vertebral osteomyelitis
Organism Number of cases (%)
Staphylococcus aureus 30/49 cases (61.2%)
Coagulase-Negative Staphylococci 10/49 cases (20.4%)
Streptococcus sp 3/49 cases (6.1%)
Fungus 2/49 cases (4.1%)
Escherichia coli 1/49 case (2.0%)
Serratia marcescens 1/49 case (2.0%)
Citrobacter sp 1/49 case (2.0%)
Stenotrophomonas maltophilia 1/49 case (2.0%)
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2–62 months). Five patients died within 6 months after
initial therapy.
Patient demographics and clinical characteristics
(Table 2).
Fourteen patients had MSSA VO and 16 had MRSA
VO. There was no statistical difference in patient age
(65.4 ± 17.2 vs. 65.9 ± 9.5, P = 0.918) between MSSA
VO and MRSA VO. There were significantly more males
in the MRSA VO group than in the MSSA VO group
(87.5% vs. 35.7%, P = 0.007). Height was significantly
higher in MRSA VO; however, there were no significant
differences in weight and BMI between the groups. The
mean number of co-morbidities for each patient in the
MRSA VO group was significantly larger than that in
the MSSA VO group (2.2 ± 1.1 vs. 1.2 ± 0.8, P = 0.011).
There was no significant difference in the prevalence of
each of the co-morbidities between the MSSA and
MRSA patients. History of preceding invasive surgical
procedures (postsurgical status) within 3 months except
for spinal surgery in the corresponding region was con-
firmed significantly more often in the MRSA VO group
than the MSSA VO group (56.3% vs. 14.3%, P = 0.026).
Seven patients with MRSA VO and 2 patients with
MSSA VO had undergone mainly gastroenterological
and cardiovascular surgeries, whereas the remaining 3
patients with MRSA VO had undergone orthopedic sur-
gery for mainly community-acquired infectious arthritis
at a previous hospital. Among the MRSA VO patients,
89% with post-surgical states were diagnosed as having
pyogenic spondylodiscitis within 1 month from the past
operation.No statistically significant differences between
the MSSA VO and MRSA VO groups were observed
with regard to pain, fever, neurological deficit, and the
onset of symptoms. In the radiographic images, the
number, localization, and staging of the vertebral body
infections as well as the presence of abscess were similar
between the MRSA and MSSA groups. In the MSSA VO
and MRSA VO groups, the mean WBC counts, CRP
levels, and Alb levels were 12.6 ± 6.0 vs. 12.2 ± 5.4 ×103/μl, 15.4 ± 9.3 vs. 15.8 ± 12.9 mg/dl, and 2.7 ± 0.6 vs.
3.0 ± 0.5 g/dl, respectively; there were no significant
differences between the 2 groups (P = 0.847, P = 0.919,
P = 0.217, respectively).
Clinical outcomes (Table 3).
There were no significant differences in the antimicro-
bial duration and length of hospital stay between the
MSSA and MRSA groups. The operation intervention
rates for MSSA and MRSA were 64.3% and 37.5%, re-
spectively, which were not significantly different (P =
0.272). Mainly Reasons for surgical were neurological
deficit in 66.7% of MRSA VO and 77.8% of MSSA VO.
In approaches of operation, anterior approach alone
were employed for 5 cases with MRSA VO and 7 case
with MSSA VO, while posterior approach with or with-
out anterior debridement were adopted for 2 cases with
MRSA VO and 2 cases with MSSA VO. Blood examin-
ation 4 weeks after the initial treatment showed that the
WBC counts in the MRSA VO group tended to be
higher than those in the MSSA VO group. There was no
apparent difference in the CRP levels between the
groups. In addition, after treatment, the WBC counts
and CRP levels in both groups improved significantly
compared with the pretreatment values. The recurrence
rate within 6 months tended to be higher in the MRSA
VO group (37.5% vs. 7.1%, P = 0.086), whereas no signifi-
cant difference in mortality was observed between the
groups (12.5% vs. 21.4%, P = 0.642). In the 16 patients
with MRSA VO, primary antibiotic therapy consisted of
linezolid in 9 patients (56.3%, mean 25 days), vanco-
mycin in 5 patients (31.3%, mean 40 days), teicoplanin
in 1 patient (6.3%, 28 days), and daptomycin in 1patinets
(6.3%, 42 days). Incidences of recurrence in patients had
undergone treatment with vancomycin and linezolid were
60% (3 patients) and 33.3% (3 patients), respectively.
Discussion
As previously reported in other studies (Zimmerli 2010;
Mylona et al. 2009; Cebrián Parra et al. 2012; Hatch
1931; Sapico & Montgomerie 1980; Yoon et al. 2010;
Corrah et al. 2011; Mete et al. 2012), SA was the most
common cause of hematogenous VO (61.2%) in our
series. Moreover, MRSA VO occurred in larger number
of patients (16) than MSSA VO (14 patients) in this
study population. Livors et al. (2008) reported that
MRSA was responsible for 57% vertebral SA infections
and MSSA for 43%. In this study, there was a signifi-
cantly greater male:female ratio in patients with MRSA
VO than in those with MSSA VO. Based on the results
of the nation-wide survey for 857 MRSA isolate,
Yanagihara indicated male predominance for this organ-
ism accounting for 66.3% of the total population
(Yanagihara et al. 2012). (Al-Nammari et al. 2007b)
reported that 85% of patients with MRSA spondylitis
Table 2 Patient demographics and clinical characteristics
MSSA-VO (14) MRSA-VO (16) P-value
Patient demographics
Age 65.4 ± 17.2 65.9 ± 9.5 0.918
Male 37.5% (5) 87.5% (14) 0.007*
Height 155.8 ± 9.5 164.3 ± 7.6 0.010*
Weight 54.4 ± 8.2 56.0 ± 11.2 0.655
BMI 22.4 ± 2.9 20.6 ± 3.5 0.154
Mean number of co-morbidities 1.2 ± 0.8 2.2 ± 1.1 0.011*
Diabetes mellitus 21.4% (3) 37.5% (6) 0.338
Heart disease 14.3% (2) 6.3% (1) 0.586
Respiratory disease 7.1% (1) 6.3% (1) 0.922
Liver disease 21.4% (3) 6.3% (1) 0.315
Urinary tract infection 7.1% (1) 6.3% (1) 0.922
Hemodialysis 7.1% (1) 6.3% (1) 0.922
Malignancy 14.3% (2) 37.5% (6) 0.226
Use steroids 14.3% (2) 18.8% (3) 0.743
Chemotherapy 0% (0) 18.8% (3) 0.228
Post-surgical states 14.3% (2) 56.3% (9) 0.026*
Clinical characteristics
Pain 100% (14) 93.8% (15) 0.467
Fever (>38°C) 64.3% (9) 50% (8) 0.484
Neurological deficit 50% (7) 50% (8) 1.000
Septic shock 21.4% (3) 43.8% (7) 0.260
Kulowski classification: acute type 57.1% (8) 62.5% (10) 0.284
Number of vertebral body infected 2.3 ± 0.8 2.2 ± 0.7 0.719
Localization of vertebral body infected
Cervical 35.7% (5) 18.8% (3)
Thoracic 28.6% (4) 37.5% (6)
Lumber 35.7% (5) 43.8% (7) 0.721
X-ray: Griffiths classification
(Destructive and osteosclerotic stage) 78.6% (11) 87.5% (14) 0.642
MRI: presence of abscess 85.7% (12) 62.5% (10) 0.226
WBC mean (x 103/ul) 12.6 ± 6.0 12.2 ± 5.4 0.847
CRP mean (mg/dl) 15.4 ± 9.3 15.8 ± 12.9 0.919
Albumin mean (g/dl) 2.7 ± 0.6 3.0 ± 0.5 0.217
*Statistically significant.
BMI indicates body mass index, WBC white blood cell, CRP C-reactive protein.
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not known.
In our series, patients with MRSA VO had significantly
more co-morbidities compared to patients with MSSA VO
(2.2 vs. 1.2). Moreover, 73% patients in this study had 2 or
more co-morbidities. (Cebrián Parra et al. 2012) reported
that 1 or more comorbid diseases were present in 73 (68%)
of 108 patients with infectious discitis. (Al-Nammari et al.
2007b) demonstrated that multiple underlying diseaseswere present in 76% patients who had hematogenous
MRSA spondylodiscitis. In previous studies that investi-
gated the type of infectious disease, such as bacteremia
(Shurland et al. 2007), endocarditis (Yoon et al. 2005), and
arthritis (Al-Nammari et al. 2007a), MRSA-infected pa-
tients had more co-morbidities than did MSSA-infected
patients. The risk for MRSA carriage may be higher be-
cause multiple underlying diseases would lead to more
opportunities for contact with medical institutions.
Table 3 Clinical outcomes
MSSA-VO (14) MRSA-VO (16) P-value
Duration of antimicrobial therapy (days) 95.4 ± 76.0 74.7 ± 42.4 0.362
Length of hospital stay (days) 103.0 ± 83.5 103.1 ± 76.0 0.998
Surgical intervention 64.3% (9) 37.5% (6) 0.272
Relapse within 6 months 7.1% (1) 37.5% (6) 0.086
Mortality within 6 months 21.4% (3) 12.5% (2) 0.642
WBC post therapy at 4th week (× 103/ul) 6.3 ± 2.1 8.6 ± 3.4 0.047*
CRP post therapy at 4th week (mg/dl) 3.1 ± 2.6 2.8 ± 2.6 0.733
*Statistically significant.
WBC indicates white blood cell, CRP C-reactive protein.
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cedure was a factor associated with occurrence of MRSA
VO. History of surgical procedures such as gastroen-
terological surgery and cardiovascular surgery within 3
months, was confirmed in 66.7% patients. (Ferreira et al.
2011) reported that MRSA liver abscess was the most
important complication associated with post-abdominal
surgery. The remaining 3 patients with related ortho-
pedic surgery were previously diagnosed as having
MRSA spondylitis after orthopedic surgery for infectious
MRSA at a different institution. Interestingly, most pa-
tients (89%) having post-surgical states had indications
of MRSA VO within 1 month after previous surgery. Al-
Nammari et al. (2007b) reported that all patients with
MRSA spondylodiscitis had undergone invasive medical
procedures in the preceding 6 months. We believe that
the reasons for MRSA spondylodiscitis were close
contact with medical institutions, intravenous catheter
use, previous antibacterial therapy, compensatory anti-
inflammatory response syndrome, or preceding MRSA
bacteremia.
The mortality rate within 6 months was 16.7% (5 cases)
in our series. Previous studies have shown that the mortal-
ity rates for spondylitis were 6%–38% (Mylona et al. 2009;
Hatch 1931; Sapico & Montgomerie 1980; Mete et al.
2012; Al-Nammari et al. 2007b; Livorsi et al. 2008; Priest
& Peacock 2005) and that the survival rate for MRSA
spondylitis was worse than that for spondylitis due to
other pathogens. In the analysis of the treatment course,
no significant difference was observed in mortality within
6 months between the MSSA VO and MRSA VO groups.
(Cosgrove et al. 2003), in a comparison with MSSA
bacteremia, reported that MRSA bacteremia was associ-
ated with a significantly higher mortality rate. However, a
recent study demonstrated no significant difference in
mortality between MRSA and MSSA bacteremia (Wang
et al. 2008).
MRSA spondylitis tends to recur after temporary
remission. In SA spondylitis including MRSA-infected
patients, recent studies have demonstrated that the re-
lapse rate was 14%–17% (Livorsi et al. 2008; Priest &Peacock 2005). (Al-Nammari et al. 2007b) showed that
29% survivors at 1 year had MRSA bacteremia and spon-
dylitis recurrence. The reason for the high recurrence
may be that vancomycin was less effective for osteomye-
litis caused by MRSA because the levels and bactericidal
activity achieved in bone may have been low (Gelfand &
Cleveland 2004; Aspinall et al. 1995). Most patients with
MRSA VO who relapsed had mainly undergone treat-
ment with vancomycin. (Gelfand & Cleveland 2004) sug-
gested that monotherapy with vancomycin for treatment
of MRSA bacteremia, while apparently successful by
conventional clinical and laboratory criteria, may not
prevent the development of VO. (Aspinall et al. 1995)
recommended that combination antibiotic therapy with
vancomycin and rifampin with or without low-dose gen-
tamicin might be useful for MRSA spondylitis. Previous
study reported that linezolid was superior to vancomycin
in the treatment MRSA infections disease, however,
linezolid can cause mild, reversible, time-dependent
myelosuppression, such as thrombocytopenia, particu-
larly when patients are treated for >14 days (Kohno
et al. 2007). The guideline in 2011 (Liu et al. 2011) pre-
pared by the Infectious Diseases Society of America
recommended that antibiotics available for parenteral
administration include vancomycin and daptomycin,
with or without rifampin. Although the adequate length
for intravenous antimicrobial therapy is unknown, a
minimum 8-week course is recommended (Liu et al.
2011). Therefore, patients with MRSA-VO should be
carefully monitored for clinical, radiographic, and la-
boratory features during and after the initial therapy, be-
cause vancomycin monotherapy may not prevent the
progression of osteomyelitis due to MRSA.
There were several limitations in this study. First, our
study was a single-institution retrospective clinical re-
view, and our small sample size did not provide enough
power to detect a difference between clinical features of
MSSA VO and MRSA VO. Moreover, the use of a multi-
variate analysis may not be fully validated to identify in-
dependent factors predicting MRSA VO in this study
population. With an average follow-up of 18 months, we
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study population. Secondly, not all of the patients under-
went examinations to detect SA carriage by nasal mu-
cosa cultures. (von Eiff et al. 2001) reported that in
patients with SA bacteremia, there was a strong correl-
ation between strains that colonized nasal tissues and
those isolated from,the blood of the patients. Accord-
ingly, in the present study, it was impossible to differen-
tiate between hematogenous SA spondylitis and the
carriage of bacteria in the nasal mucosa as a cause of
infection.
Conclusions
Our study demonstrated that MRSA spondylitis was as-
sociated with male predominance and multiple co-
morbidities. Post-surgical states within 3 months were
the most important underlying condition of patients
with MRSA spondylitis. We supposed that the risk of
MRSA carriage might be higher because multiple under-
lying diseases would lead to more opportunities for
contact with medical institutions. The recurrence rate
within 6 months tended to be higher in the patients with
MRSA VO, but no significant difference in mortality was
observed between the groups. Based on these study re-
sults, we propose that hematogenous SA spondylitis
should be considered as the initial tentative diagnosis to
start antimicrobial administration for patients with VO,
and then patients with MRSA VO should be carefully
monitored for recurrence by sequential clinical, radio-
graphic, and laboratory examinations during the treat-
ment course.
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